The effects of guanfacine on context processing abnormalities in schizotypal personality disorder
Open accessAbstract
Background The signature of impaired cognition in people with schizotypal personality disorder (SPD) may be centrally related to working memory impairments. Guanfacine, an alpha2A agonist that acts post-synaptically in the prefrontal cortex (PFC), has shown potential for reducing working memory limitations in other populations. This study examined the potential of guanfacine for improving context processing, a feature of working memory, in SPD. Methods 29 individuals with SPD entered into a 4-week, randomized parallel-design, double-blind, placebo-controlled trial of guanfacine treatment, followed by a 4-week open-label extension. A modified version of the AX-Continuous Performance Test (AX-CPT) was administered. On this task, evidence of intact context processing includes few BX errors (false cue, correct probe) and higher levels of AY errors (correct cue, false probe). Results At the end of double-blind treatment, participants treated with guanfacine demonstrated a significant reduction in BX errors and a small but significant increase in AY errors, a pattern that was not seen in the participants treated with placebo. Conclusions SPD participants improved in their context processing toward a normal response bias, making fewer BX and more AY errors, after being treated with guanfacine.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Guanfacine can improve working memory in schizotypal patients.
“The work of Margaret McClure has shown that guanfacine can improve working memory (McClure, Barch, Romero, Harvey, & Siever, 2007)”
From Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species (2020) · cites this paper as McClure, Barch, Romero, Harvey, & Siever, 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Context, cortex, and dopamine: A connectionist approach to behavior and biology in schizophrenia.
Cohen, J. D., & Servan‐Schreiber, D. (1992) · Psychological Review · doi:10.1037/0033-295x.99.1.45 · Cited by 1,494 · see citing works
Selective Deficits in Prefrontal Cortex Function in Medication-Naive Patients With Schizophrenia
Barch, D. M., Carter, C. S., Braver, T. S., Sabb, F. W., MacDonald, A. W., Noll, D. C., & Cohen, J. D. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.3.280 · Cited by 615 · see citing works
Self-citationCohen, J. D., Barch, D. M., Carter, C., & Servan‐Schreiber, D. (1999) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.108.1.120 · Cited by 612 · see citing works
Self-citationCognition and control in schizophrenia: a computational model of dopamine and prefrontal function
Braver, T. S., Barch, D. M., & Cohen, J. D. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00116-x · Cited by 507 · see citing works
Self-citationThe primacy of cognition in schizophrenia
Heinrichs, R. W. (2005) · American Psychologist · doi:10.1037/0003-066x.60.3.229 · Cited by 338 · see citing works
Barch, D. M., Carter, C. S., MacDonald, A. W., Braver, T. S., & Cohen, J. D. (2003) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.112.1.132 · Cited by 255 · see citing works
Self-citationChapter 19 Dopamine, cognitive control, and schizophrenia: the gating model
Braver, T. S., & Cohen, J. D. (1999) · Progress in Brain Research · doi:10.1016/s0079-6123(08)63082-4 · Cited by 159 · see citing works
Friedman, J. I., Adler, D. N., & Davis, K. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00232-2 · Cited by 147 · see citing works
The Boundaries of Schizophrenia
Siever, L. J., Kalus, O., & Keefe, R. S. E. (1993) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30171-0 · Cited by 135 · see citing works
Self-citationNeuropsychological dysfunction in schizotypal personality disorder: A profile analysis
Voglmaier, M. M., Seidman, L. J., Salisbury, D. F., & McCarley, R. W. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00056-x · Cited by 132 · see citing works
Adrenergic targets for the treatment of cognitive deficits in schizophrenia
Arnsten, A. F. T. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1724-3 · Cited by 127 · see citing works
Neuropsychological Performance in Schizotypal Personality Disorder: Importance of Working Memory
Mitropoulou, V., Harvey, P. D., Zegarelli, G., New, A. S., Silverman, J. M., & Siever, L. J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1896 · Cited by 119 · see citing works
Self-citationGuanfacine treatment of cognitive impairment in schizophrenia
Friedman, J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00249-4 · Cited by 113 · see citing works
Context-Processing Deficits in Schizotypal Personality Disorder.
Barch, D. M., Mitropoulou, V., Harvey, P. D., New, A. S., Silverman, J. M., & Siever, L. J. (2004) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.113.4.556 · Cited by 96 · see citing works
Self-citationCognitive functions in schizotypal personality disorder
Cadenhead, K. S., Perry, W., Shafer, K., & BRAFF, D. L. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00147-9 · Cited by 94 · see citing works
Roitman, S. E. L., Cornblatt, B. A., Bergman, A. J., Obuchowski, M., Mitropoulou, V., Keefe, R. S. E., Silverman, J. M., & Siever, L. J. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.5.655 · Cited by 79 · see citing works
Self-citationVisuospatial working memory in schizotypal personality disorder patients
Roitman, S. E. L., Mitropoulou, V., Keefe, R. S. E., Silverman, J. M., Serby, M., Harvey, P. D., Reynolds, D. A., Mohs, R. C., & Siever, L. J. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00085-7 · Cited by 75 · see citing works
Self-citationReduced cognitive inhibition in schizotypy
Moritz, S., & Maß, R. (1997) · British Journal of Clinical Psychology · doi:10.1111/j.2044-8260.1997.tb01244.x · Cited by 63 · see citing works
Panic Attacks During Placebo Procedures in the Laboratory
Goetz, R. R. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820160050006 · Cited by 62 · see citing works
CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers
Rapaport, M. H., McAllister, C. G., Pickar, D., Tamarkin, L., Kirch, D. G., & Paul, S. M. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00008-x · Cited by 54 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Wang, M., Ramos, B. P., Paspalas, C. D., Shu, Y., Simen, A., Duque, A., Vijayraghavan, S., Brennan, A., Dudley, A., Nou, E., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.015 · Cited by 672 · see citing works
Adrenergic pharmacology and cognition: Focus on the prefrontal cortex
Ramos, B. P., & Arnsten, A. F. T. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.006 · Cited by 641 · see citing works
Catecholamine Influences on Dorsolateral Prefrontal Cortical Networks
Arnsten, A. F. T. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.01.027 · Cited by 493 · see citing works
Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
Lesh, T. A., Niendam, T. A., Minzenberg, M., & Carter, C. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.156 · Cited by 495 · see citing works
Self-citationCognitive enhancement as a pharmacotherapy target for stimulant addiction
Sofuoglu, M. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02791.x · Cited by 158 · see citing works
Schizotypal Personality Disorder: A Current Review
Rosell, D. R., Futterman, S. E., McMaster, A., & Siever, L. J. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0452-1 · Cited by 142 · see citing works
Self-citationSchizotypal Personality Disorder
Chemerinski, E., Triebwasser, J., Roussos, P., & Siever, L. J. (2012) · Journal of Personality Disorders · doi:10.1521/pedi_2012_26_053 · Cited by 117 · see citing works
Self-citationPharmacological Cognitive Enhancement in Schizophrenia
Harvey, P. D. (2009) · Neuropsychology Review · doi:10.1007/s11065-009-9103-4 · Cited by 95 · see citing works
Self-citationStrassnig, M., Bowie, C. R., Pinkham, A. E., Penn, D. L., Twamley, E. W., Patterson, T. L., & Harvey, P. D. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.06.018 · Cited by 92 · see citing works
Self-citationGuanfacine for the treatment of cognitive disorders: a century of discoveries at Yale.
Arnsten, A. F. T., & Jin, L. E. (2012) · Europe PMC (PubMed Central) · Cited by 87 · see citing works
Evidence-based pharmacotherapy for personality disorders
Ripoll, L. H., Triebwasser, J., & Siever, L. J. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000071 · Cited by 83 · see citing works
Self-citationThe use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder
Arnsten, A. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.133 · Cited by 80 · see citing works
Arnsten, A. F. T. (2020) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2020.107327 · Cited by 75 · see citing works
Shields, A. D., Wang, Q., & Winder, D. G. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.06.022 · Cited by 68 · see citing works
Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review
Kirchner, S. K., Roeh, A., Nolden, J., & Hasan, A. (2018) · Schizophrenia · doi:10.1038/s41537-018-0062-8 · Cited by 66 · see citing works
McClure, M. M., Harvey, P. D., Goodman, M. S., Triebwasser, J., New, A. S., Koenigsberg, H. W., Sprung, L., Flory, J. D., & Siever, L. J. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.5 · Cited by 62 · see citing works
Self-citationBlackman, R. K., MacDonald, A. W., & Chafee, M. V. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.118 · Cited by 56 · see citing works
Alpha-2 Adrenergic Receptors and Attention-Deficit/Hyperactivity Disorder
Bidwell, L. C., Dew, R. E., & Kollins, S. H. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0136-4 · Cited by 54 · see citing works
McClure, M. M., Graff, F., Triebwasser, J., Perez-Rodriguez, M., Rosell, D. R., Koenigsberg, H., Hazlett, E. A., Siever, L. J., Harvey, P. D., & New, A. S. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18030349 · Cited by 38 · see citing works
Self-citationCognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms
Keefe, R. S. E., Harvey, P. D., Khan, A., Saoud, J. B., Staner, C., Davidson, M., & Luthringer, R. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m11753 · Cited by 36 · see citing works
Self-citationSchizotypy and language: A review
Michael Kiang, A. (2009) · Journal of Neurolinguistics · doi:10.1016/j.jneuroling.2009.03.002 · Cited by 34 · see citing works
Toriumi, K., Miyashita, M., Suzuki, K., Yamasaki, N., Yasumura, M., Horiuchi, Y., Yoshikawa, A., Asakura, M., Usui, N., Itokawa, M., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01381-z · Cited by 34 · see citing works
Bilder, R. M., Loo, S. K., McGough, J. J., Whelan, F., Hellemann, G., Sugar, C., Del’Homme, M., Sturm, A., Cowen, J., Hanada, G., et al. (2016) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.05.016 · Cited by 29 · see citing works
Pharmacological Augmentation of Psychosocial and Remediation Training Efforts in Schizophrenia
Harvey, P. D., & Sand, M. S. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00177 · Cited by 29 · see citing works
Self-citationChun, C. A., Ciceron, L., & Kwapil, T. R. (2018) · Journal of Abnormal Psychology · doi:10.1037/abn0000383 · Cited by 27 · see citing works
The Schizophrenia Spectrum Personality Disorders
Chemerinski, E., & Siever, L. J. (2010) · Wiley eBooks · doi:10.1002/9781444327298.ch5 · Cited by 27 · see citing works
Self-citationOff-label use of atypical antipsychotics in personality disorders
Rosenbluth, M. J., & Sinyor, M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.608351 · Cited by 22 · see citing works
Barcelos, N. M., Van Ness, P. H., Wagner, A. F., MacAvoy, M. G., Mecca, A. P., Anderson, G. M., Trentalange, M., Hawkins, K. A., Sano, M., Arnsten, A. F. T., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.05.033 · Cited by 21 · see citing works
Pre- versus Postsynaptic Signaling by α2-Adrenoceptors
Gilsbach, R., Albarrán-Juárez, J., & Hein, L. (2011) · Current topics in membranes · doi:10.1016/b978-0-12-384921-2.00007-0 · Cited by 19 · see citing works
Emerging 5-HT receptor antagonists for the treatment of Schizophrenia
Jones, M. T., Strassnig, M., & Harvey, P. D. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1773792 · Cited by 19 · see citing works
Self-citationMcClure, M. M., Koenigsberg, H. W., Reynolds, D. A., Goodman, M. S., New, A. S., Trestman, R. L., Silverman, J. M., Harvey, P. D., & Siever, L. J. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181accfd9 · Cited by 19 · see citing works
Self-citationCognitive Control in Schizophrenia
Barch, D. M., & Sheffield, J. M. (2017) · Wiley eBooks · doi:10.1002/9781118920497.ch31 · Cited by 20 · see citing works
Self-citationHack, L. M., Jubeir, J., Hilton, R. A., Tozzi, L., Boyar, L., Zhang, X., Lyons, T., Jo, B., O'Hara, R. M., Schatzberg, A. F., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00510-7 · Cited by 11 · see citing works
Review of pharmacologic treatment in cluster A personality disorders
Koch, J. M., Modesitt, T., Palmer, M., Ward, S. L., Martin, B., Wyatt, R., & Thomas, C. J. (2016) · Mental Health Clinician · doi:10.9740/mhc.2016.03.75 · Cited by 11 · see citing works
Chu, Z., Han, W., Liu, P., Liu, F., Lei, G., Deng, L., Yang, L., & Dang, Y. (2021) · BMC Neuroscience · doi:10.1186/s12868-021-00677-6 · Cited by 9 · see citing works
Leung, W. W.-M. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s1500 · Cited by 9 · see citing works
Brocos‐Mosquera, I., Gabilondo, A. M., Dı́ez-Alarcia, R., Muguruza, C., Erdozain, A. M., Meana, J. J., & Callado, L. F. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.05.012 · Cited by 9 · see citing works
Harvey, P. D., & Jones, M. T. (2019) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2019.100152 · Cited by 8 · see citing works
Self-citationSystems Level Modeling of Cognitive Control in Psychiatric Disorders
Barch, D. M., Culbreth, A. J., & Sheffield, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809825-7.00006-7 · Cited by 7 · see citing works
Self-citationPharmacotherapy of personality disorders: what we know and what we have to search for
Bozzatello, P., Ghirardini, C., Uscinska, M., Rocca, P., & Bellino, S. (2017) · Future Neurology · doi:10.2217/fnl-2017-0010 · Cited by 7 · see citing works
Challman, K. N., Rosell, D. R., Barch, D. M., Koenigsberg, H. W., Harvey, P. D., Hazlett, E. A., Pérez-Rodríguez, M. M., New, A. S., & McClure, M. M. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.04.007 · Cited by 6 · see citing works
Self-citationEvidence-based pharmacotherapy of personality disorders
Ripoll, L. H., Triebwasser, J., & Siever, L. J. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.015 · Cited by 6 · see citing works
Self-citationRecent approaches to pharmacotherapy of personality disorders
Bellino, S., Rinaldi, C., Bozzatello, P., & Bogetto, F. (2011) · Neuropsychiatry · doi:10.2217/npy.11.17 · Cited by 6 · see citing works
Pharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders
Venero, C. (2015) · Cognitive Enhancement · doi:10.1016/b978-0-12-417042-1.00010-3 · Cited by 4 · see citing works
Remediation and Cognitive Enhancers in Schizotypal Personality Disorder
Graff, F. S., McClure, M. M., & Siever, L. J. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0027-0 · Cited by 4 · see citing works
Self-citationPersönlichkeitsstörungen – Diagnostische Konzepte – Neurobiologie-Pharmakotherapie
Kapfhammer, H. (2008) · Psychiatrie und Psychotherapie · doi:10.1007/s11326-008-0004-6 · Cited by 4 · see citing works
Gundersen, K. B., Arnfred, B., Albert, N., Rasmussen, A. R., Ebdrup, B. H., Polari, A., Nelson, B., & Glenthøj, L. B. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.12.008 · Cited by 3 · see citing works
Comorbidities in Schizophrenia: Challenges for Researchers and Clinicians
Opler, L. A., Hwang, M. Y., & Opler, M. G. A. (2013) · Psychiatric Annals · doi:10.3928/00485713-20131003-03 · Cited by 3 · see citing works
Vova, J. A. (2021) · Journal of Pediatric Rehabilitation Medicine · doi:10.3233/prm-200677 · Cited by 3 · see citing works
Pharmacological approaches to cognitive enhancement
Harvey, P. D. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003872.016 · Cited by 2 · see citing works
Self-citationEvidence-Based Pharmacotherapy for Personality Disorders
Ripoll, L. H., Triebwasser, J., & Siever, L. J. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.2.225 · Cited by 2 · see citing works
Self-citationPersonality Disorders in Older Age
Brudey, C. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20210007 · Cited by 2 · see citing works
Gabbard, G. O., Schmahl, C. G., Siever, L. J., & Iskander, E. G. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52002-9.00027-9 · Cited by 1 · see citing works
Self-citationWoolley, B. (2023) · Issues in Mental Health Nursing · doi:10.1080/01612840.2023.2242236 · Cited by 1 · see citing works
Negative Schizotypy: Now That We Know What It Is, Should We Do Something About It?
Harvey, P. D. (2024) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2024.100354 · Cited by 1 · see citing works
Self-citationAdvances in Treatment for Personality Disorders
Biskin, R., & Paris, J. (2018) · Advances in Psychiatry · doi:10.1007/978-3-319-70554-5_19 · Cited by 1 · see citing works
McGurk, S. R. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020144 · Cited by 1 · see citing works
Schizotypal Personality Disorder
Garakani, A., & Siever, L. J. (2015) · The Encyclopedia of Clinical Psychology · doi:10.1002/9781118625392.wbecp390 · Cited by 1 · see citing works
Self-citationCurrent awareness in human psychopharmacology
(2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.898 · Cited by 1 · see citing works
Mason, M. N., Jacobs, N. N., & Pai, L. (2016) · Springer eBooks · doi:10.1007/978-3-319-23669-8_24 · Cited by 1 · see citing works
Assessment and treatment of cognitive impairment and related features
Harvey, P. D. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003872.014
Self-citationBayer, L. E. (2008) · eCommons (Cornell University)
Pharmacotherapy of Personality Disorders
Öyekçin, D. G., & Yıldız, D. (2012) · Journal of Mood Disorders · doi:10.5455/jmood.20120328094704
Pai, L., Piasecki, M. M., & Mason, M. N. (2008) · Springer eBooks · doi:10.1007/978-0-387-78585-1_24
Farooq, S., & Ayub, M. (2022) · Springer eBooks · doi:10.1007/978-3-031-09058-5_5
Disintegration and context processing in AX-CPT
Soljaga, M., & Knežević, G. (2022) · Psihologija · doi:10.2298/psi211010026s
Larrauri, C. A., Harvey, P. D., & Kane, J. M. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s419177
Self-citationChapter 56. Treatment of Personality Disorders
Hollander, E., Vats, T., & Desilva, N. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as56
Gender differences in semantic facilitation and verbal recall in schizotypal personality disorder
Voglmaier, M. M., Dickey, C. C., McCarley, R. W., & Niznikiewicz, M. M. (2026) · Schizophrenia · doi:10.1038/s41537-025-00727-6
Sergeev, A. I., & Nekrasov, P. V. (2025) · BIOPHYSICS · doi:10.1134/s0006350925701052
- Authors
- McClure, M. M., Barch, D. M., Romero, M. J., Minzenberg, M. J., Triebwasser, J., Harvey, P. D., & Siever, L. J.
- Affiliations
- New York/New Jersey VA Health Care Network (US)
- Washington University in St. Louis (US)
- University of California Davis Medical Center (US)
- Corresponding author
- McClure, Margaret M.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2007-05
- Volume
- 61
- Issue
- 10
- Pages
- 1157-1160
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2109671525
- Cited by
- 70
- References
- 20
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 2 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 3 · 2015: 2 · 2014: 2 · 2013: 5 · 2012: 5
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 56140, MH 63116)
- National Center for Research Resources
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Keywords
- guanfacine, schizotypal personality disorder, context processing, working memory, prefrontal cortex, response bias, false alarm errors
- MeSH terms
- Adrenergic alpha-Agonists, Adult, Cognition Disorders, Double-Blind Method, Female, Humans, Male, Memory, Short-Term, Middle Aged, Neuropsychological Tests, Reaction Time, Schizotypal Personality Disorder, Guanfacine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
